You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
遠大醫藥(00512):全球創新產品STC3141在比利時完成COVID-19的IIa期臨試首四例患者入組給藥
格隆匯 05-24 17:54

格隆匯5月24日丨遠大醫藥(00512)發佈公吿,集團全資擁有附屬公司Grand Medical Pty Ltd(一間集團在澳洲設立的創新藥研發中心)正在開發的用於重症感染領域的全球創新藥物STC3141,日前在比利時順利完成用於治療重症2019冠狀病毒病(COVID-19)患者的IIa期臨牀試驗的首四例患者入組,並順利完成連續給藥。

此次STC3141在比利時完成治療重症COVID-19患者的IIa期臨牀試驗的首四例患者入組給藥,旨在研究和評估藥物在治療因感染COVID-19所引發的病毒性肺炎重症患者中的安全性、有效性及最佳給藥策略,進一步擴大產品的適用範圍,積累更多資料綜合評估後期臨牀試驗的風險和效益,以加快產品的全球開發進程。

公司表示,集團一直高度重視創新產品和先進技術的研發,以患者需求為核心,以科技創新為驅動,針對尚未滿足的臨牀需求,加大對全球創新產品和先進技術的投入,豐富和完善產品管線及產業佈局,採用“全球化運營佈局,雙循環經營發展”策略,形成國內國際雙循環聯動發展並相互促進的新格局,充分發揮集團的產業優勢和研發實力,快速將科技創新產品落地上市,為全球患者提供更先進更多樣的治療方案。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account